{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T09:42:36Z","timestamp":1790502156887,"version":"4.1.0"},"reference-count":57,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2017,7,27]],"date-time":"2017-07-27T00:00:00Z","timestamp":1501113600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0180869","type":"journal-article","created":{"date-parts":[[2017,7,27]],"date-time":"2017-07-27T17:48:43Z","timestamp":1501177723000},"page":"e0180869","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":49,"title":["Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin\/kexin type 9"],"prefix":"10.1371","volume":"12","author":[{"given":"Rocco","family":"Romagnuolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey A.","family":"Scipione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santica M.","family":"Marcovina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Gemin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil G.","family":"Seidah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Boffa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2643-2288","authenticated-orcid":true,"given":"Marlys L.","family":"Koschinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,7,27]]},"reference":[{"issue":"26","key":"ref1","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"R Clarke","year":"2009","journal-title":"N Engl J Med"},{"issue":"22","key":"ref2","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"PR Kamstrup","year":"2009","journal-title":"JAMA"},{"issue":"4","key":"ref3","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.ecl.2014.08.002","article-title":"Lipoprotein(a): an important cardiovascular risk factor and a clinical conundrum","volume":"43","author":"ML Koschinsky","year":"2014","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"6144","key":"ref4","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/330132a0","article-title":"cDNA sequence of human apolipoprotein(a) is homologous to plasminogen","volume":"330","author":"JW McLean","year":"1987","journal-title":"Nature"},{"issue":"4","key":"ref5","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/hmg\/2.4.361","article-title":"The apolipoprotein(a) kringle IV repeats which differ from the major repeat kringle are present in variably-sized isoforms","volume":"2","author":"YY van der Hoek","year":"1993","journal-title":"Hum Mol Genet"},{"issue":"7","key":"ref6","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/hmg\/2.7.933","article-title":"Molecular definition of the extreme size polymorphism in apolipoprotein(a","volume":"2","author":"C Lackner","year":"1993","journal-title":"Hum Mol Genet"},{"issue":"12","key":"ref7","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1016\/S0022-2275(20)37461-7","article-title":"Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans","volume":"37","author":"SM Marcovina","year":"1996","journal-title":"J Lipid Res"},{"issue":"1","key":"ref8","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2796.2012.02592.x","article-title":"Lipoprotein(a): resurrected by genetics","volume":"273","author":"F Kronenberg","year":"2013","journal-title":"J Intern Med"},{"issue":"6","key":"ref9","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1172\/JCI117292","article-title":"The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate","volume":"93","author":"DJ Rader","year":"1994","journal-title":"J Clin Invest"},{"issue":"8","key":"ref10","doi-asserted-by":"crossref","first-page":"5048","DOI":"10.1074\/jbc.272.8.5048","article-title":"Influence of allelic variation on apolipoprotein(a) folding in the endoplasmic reticulum","volume":"272","author":"AL White","year":"1997","journal-title":"J Biol Chem"},{"issue":"1","key":"ref11","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1172\/JCI115855","article-title":"Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations","volume":"90","author":"E Boerwinkle","year":"1992","journal-title":"J Clin Invest"},{"issue":"7","key":"ref12","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1517\/14728222.2014.920326","article-title":"Lipoprotein(a) as a therapeutic target in cardiovascular disease","volume":"18","author":"M Koschinsky","year":"2014","journal-title":"Expert Opin Ther Targets"},{"issue":"3","key":"ref13","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S0022-2275(20)37595-7","article-title":"Interaction of a recombinant form of apolipoprotein[a] with human fibroblasts and with the human hepatoma cell line HepG2","volume":"37","author":"SP Tam","year":"1996","journal-title":"J Lipid Res"},{"issue":"2","key":"ref14","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S0006-291X(81)80179-9","article-title":"Uptake of Lp (a) lipoprotein by cultured fibroblasts","volume":"102","author":"CH Floren","year":"1981","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"ref15","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0014-5793(81)81153-2","article-title":"Binding of LP(a) to the low density lipoprotein receptor of human fibroblasts","volume":"132","author":"L Havekes","year":"1981","journal-title":"FEBS Lett"},{"issue":"2","key":"ref16","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1172\/JCI113086","article-title":"Lipoprotein binding to cultured human hepatoma cells","volume":"80","author":"F Krempler","year":"1987","journal-title":"J Clin Invest"},{"issue":"10","key":"ref17","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0022-2275(20)37140-6","article-title":"Cellular uptake of lipoprotein[a] by mouse embryonic fibroblasts via the LDL receptor and the LDL receptor-related protein","volume":"38","author":"T Reblin","year":"1997","journal-title":"J Lipid Res"},{"issue":"9","key":"ref18","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1172\/JCI119753","article-title":"The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor","volume":"100","author":"KM Argraves","year":"1997","journal-title":"J Clin Invest"},{"issue":"3","key":"ref19","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0014-5793(93)81087-G","article-title":"Heterogeneous lipoprotein (a) size isoforms differ by their interaction with the low density lipoprotein receptor and the low density lipoprotein receptor-related protein\/alpha 2-macroglobulin receptor","volume":"325","author":"W Marz","year":"1993","journal-title":"FEBS Lett"},{"issue":"3","key":"ref20","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1161\/01.ATV.19.3.552","article-title":"Identification of megalin\/gp330 as a receptor for lipoprotein(a) in vitro","volume":"19","author":"A Niemeier","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9","key":"ref21","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1194\/jlr.M038877","article-title":"Scavenger receptor-BI is a receptor for lipoprotein(a)","volume":"54","author":"XP Yang","year":"2013","journal-title":"J Lipid Res"},{"issue":"12","key":"ref22","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1194\/jlr.M500249-JLR200","article-title":"Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a]","volume":"46","author":"WJ Cain","year":"2005","journal-title":"J Lipid Res"},{"issue":"3","key":"ref23","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1172\/JCI117794","article-title":"The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans","volume":"95","author":"DJ Rader","year":"1995","journal-title":"J Clin Invest"},{"issue":"6","key":"ref24","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","article-title":"Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)","volume":"129","author":"AV Khera","year":"2014","journal-title":"Circulation"},{"issue":"5","key":"ref25","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1172\/JCI114602","article-title":"Overexpression of human low density lipoprotein receptors leads to accelerated catabolism of Lp(a) lipoprotein in transgenic mice","volume":"85","author":"SL Hofmann","year":"1990","journal-title":"J Clin Invest"},{"issue":"19","key":"ref26","first-page":"1982","article-title":"Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation","volume":"63","author":"R Alonso","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"ref27","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1161\/01.ATV.20.2.522","article-title":"Lipoprotein(a) in homozygous familial hypercholesterolemia","volume":"20","author":"HG Kraft","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"25","key":"ref28","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/j.jacc.2012.03.007","article-title":"Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease, SAR236553\/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy","volume":"59","author":"JM McKenney","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"ref29","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1056\/NEJMoa1201832","article-title":"Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia","volume":"367","author":"EM Roth","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"ref30","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1161\/CIRCULATIONAHA.113.001969","article-title":"AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial","volume":"128","author":"NR Desai","year":"2013","journal-title":"Circulation"},{"issue":"13","key":"ref31","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2014.01.006","article-title":"Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials","volume":"63","author":"FJ Raal","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"33","key":"ref32","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1093\/eurheartj\/ehu085","article-title":"Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials","volume":"35","author":"EA Stein","year":"2014","journal-title":"Eur Heart J"},{"issue":"5","key":"ref33","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.amjcard.2014.05.060","article-title":"Effect of alirocumab, a monoclonal proprotein convertase subtilisin\/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials)","volume":"114","author":"D Gaudet","year":"2014","journal-title":"Am J Cardiol"},{"issue":"6","key":"ref34","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1194\/jlr.P065334","article-title":"PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role","volume":"57","author":"FJ Raal","year":"2016","journal-title":"J Lipid Res"},{"issue":"4","key":"ref35","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/humu.20882","article-title":"Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease","volume":"30","author":"M Abifadel","year":"2009","journal-title":"Hum Mutat"},{"key":"ref36","article-title":"PCSK9 R46L loss-of-function mutation reduces lipoprotein(a), LDL cholesterol, and risk of aortic valve stenosis","author":"A Langsted","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"18","key":"ref37","doi-asserted-by":"crossref","first-page":"11649","DOI":"10.1074\/jbc.M114.611988","article-title":"Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin\/kexin type 9 through the low density lipoprotein receptor","volume":"290","author":"R Romagnuolo","year":"2015","journal-title":"J Biol Chem"},{"issue":"3","key":"ref38","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1172\/JCI1240","article-title":"Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants","volume":"101","author":"A Rohlmann","year":"1998","journal-title":"J Clin Invest"},{"issue":"18","key":"ref39","doi-asserted-by":"crossref","first-page":"8453","DOI":"10.1073\/pnas.92.18.8453","article-title":"Normal plasma lipoproteins and fertility in gene-targeted mice homozygous for a disruption in the gene encoding very low density lipoprotein receptor","volume":"92","author":"PK Frykman","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"ref40","doi-asserted-by":"crossref","first-page":"e64145","DOI":"10.1371\/journal.pone.0064145","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1)","volume":"8","author":"M Canuel","year":"2013","journal-title":"PLoS One"},{"issue":"10","key":"ref41","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/BF02618288","article-title":"Mouse liver cell culture. I. Hepatocyte isolation","volume":"17","author":"JE Klaunig","year":"1981","journal-title":"In Vitro"},{"issue":"31","key":"ref42","doi-asserted-by":"crossref","first-page":"9978","DOI":"10.1021\/bi049536d","article-title":"Identification of sequences in apolipoprotein(a) that maintain its closed conformation: a novel role for apo(a) isoform size in determining the efficiency of covalent Lp(a) formation","volume":"43","author":"L Becker","year":"2004","journal-title":"Biochemistry"},{"issue":"8","key":"ref43","doi-asserted-by":"crossref","first-page":"e72113","DOI":"10.1371\/journal.pone.0072113","article-title":"PCSK9 prosegment chimera as novel inhibitors of LDLR degradation","volume":"8","author":"YG Saavedra","year":"2013","journal-title":"PLoS One"},{"issue":"8","key":"ref44","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1172\/JCI63563","article-title":"Hepatic sortilin regulates both apolipoprotein B secretion and LDL catabolism","volume":"122","author":"A Strong","year":"2012","journal-title":"J Clin Invest"},{"issue":"12","key":"ref45","doi-asserted-by":"crossref","first-page":"8279","DOI":"10.1074\/jbc.M112.421370","article-title":"Low density lipoprotein binds to proprotein convertase subtilisin\/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation","volume":"288","author":"T Kosenko","year":"2013","journal-title":"J Biol Chem"},{"issue":"47","key":"ref46","doi-asserted-by":"crossref","first-page":"48865","DOI":"10.1074\/jbc.M409699200","article-title":"NARC-1\/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol","volume":"279","author":"S Benjannet","year":"2004","journal-title":"J Biol Chem"},{"issue":"6","key":"ref47","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/j.1600-0854.2007.00562.x","article-title":"The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR","volume":"8","author":"N Nassoury","year":"2007","journal-title":"Traffic"},{"issue":"12","key":"ref48","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1194\/jlr.R026658","article-title":"The PCSK9 decade","volume":"53","author":"G Lambert","year":"2012","journal-title":"J Lipid Res"},{"issue":"4","key":"ref49","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1074\/jbc.M708098200","article-title":"The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2","volume":"283","author":"S Poirier","year":"2008","journal-title":"J Biol Chem"},{"issue":"4","key":"ref50","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.116.025253","article-title":"Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans","volume":"135","author":"G Reyes-Soffer","year":"2017","journal-title":"Circulation"},{"issue":"12","key":"ref51","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1161\/ATVBAHA.115.306136","article-title":"Effects of Extended-Release Niacin on the Postprandial Metabolism of Lp(a) and ApoB-100-Containing Lipoproteins in Statin-Treated Men With Type 2 Diabetes Mellitus","volume":"35","author":"EM Ooi","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref52","article-title":"Effects of Extended-Release Nicotinic Acid on Apolipoprotein (a) Kinetics in Hypertriglyceridemic Patients","author":"M Croyal","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"ref53","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jacbts.2016.06.006","article-title":"PCSK9 modulates the secretion but not the cellular uptake of lipoprotein(a) ex vivo","volume":"1","author":"EF Villard","year":"2016","journal-title":"JACC Basic Trans Sci"},{"issue":"1","key":"ref54","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1161\/CIRCRESAHA.116.308811","article-title":"PCSK9 Association With Lipoprotein(a)","volume":"119","author":"H Tavori","year":"2016","journal-title":"Circulation Research"},{"issue":"4","key":"ref55","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1161\/CIRCRESAHA.115.306471","article-title":"From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk","volume":"118","author":"MD Shapiro","year":"2016","journal-title":"Circulation Research"},{"key":"ref56","article-title":"ALN-PCSsc, an RNAi Investigational Agent That Inhibits PCSK9 Synthesis With the Potential for Effective Bi-Annual Dosing: Interim Results","volume":"2015","author":"K Fitzgerald","journal-title":"American Heart Association Scientific Sessions"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1476-511X-7-22","article-title":"Plasma PCSK9 levels are significantly modified by statins and fibrates in humans","volume":"7","author":"J Mayne","year":"2008","journal-title":"Lipids Health Dis"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0180869","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,31]],"date-time":"2022-07-31T15:11:35Z","timestamp":1659280295000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0180869"}},"subtitle":[],"editor":[{"given":"Maria Cristina","family":"Vinci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,7,27]]},"references-count":57,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,7,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0180869","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,27]]}}}